3P Biopharmaceuticals renews its “Credit Impôt Recherche” (CIR) by the French Ministry of Higher Education and Research

CIR Certificate is Extended for a Four-Year Period Between 2020-2024

3P Biopharmaceuticals, a European leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has successfully extended its French CIR certificate for another four-year period: 2020-2024.

The CIR “Credit Impôt Recherche” or French Research Tax Credit is a corporate tax relief measure that allows French companies to declare innovative research costs and obtain a significant reduction on their tax bill.

This renewal allows 3P’s French customers the opportunity to receive an important percentage of their R&D costs in tax credits. Therefore, 3P Biopharmaceuticals continues to bring added-value to their French clients thanks to this opportunity to increase the quality, safety and efficacy of their biologic drugs.

3P Biopharmaceuticals already counts with a strong French client portfolio at different stages of their biologics development who have embraced this interesting incentive over the last years.

As 3P Biopharmaceuticals CEO Dámaso Molero explains: “It is wonderful news to renew CIR certificate for another four years to confirm 3P Biopharmaceuticals, once again, as a valuable and competitive CDMO partner for French biotech and pharma companies interested in developing biologics.

3P Biopharmaceuticals once again demonstrates its capacity to carry out processes development and manufacturing of molecules developed within diverse therapeutic applications. At the same time, 3P Biopharmaceuticals consolidates a competitive position among the most esteemed CDMOs in Europe.

Related Content

3P Biopharmaceuticals reinforces its commitment to female talent with its participation in the programme ‘Lidera en femenino-STEM’

The Head of Quality Assurance & Qualified Person at 3P Biopharmaceuticals, Susana Santesteban, has attended ‘Lidera en femenino-STEM’, a course that aims to help promote the career advancement of STEM women.
Read more

3P Biopharmaceuticals and Buzzard Pharmaceuticals start a collaboration to develop a new treatment to combat solid tumours

3P Biopharmaceuticals and Buzzard Pharmaceuticals have entered into a partnership agreement for manufacturing of the potent IL-1 inhibitor Isunakinra, a recombinant protein for cancer indications.
Read more

Working in biotechnology means working to improve the planet and people’s lives

Ion Arocena, CEO of AseBio, has delivered a speech at an event organised as part of the agreement that 3P Biopharmaceuticals has signed with the School of Pharmacy and Nutrition of the University of Navarra to promote training in Biotechnology
Read more

Get in touch

Let’s discuss your biologics journey.

Discover more about our people, our passion, and how we can work together to improve lives.